Clinical Trial Highlights

• Profiling Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Targetable Genetic Alterations
• The UK START Trials: 10-Year Follow-Up Results
• HERA TRIAL: 2 Years versus 1 Year of Trastuzumab after Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up
• Effectiveness of Letrozole Compared with Tamoxifen for Patients with Lobular Carcinoma in the BIG 1–98 Trial
• Neurocognitive Impact in Adjuvant Chemotherapy for Breast Cancer Linked to Fatigue: A Prospective Functional MRI Study
• ATLAS: 10 versus 5 Years of Adjuvant Tamoxifen in ER-Positive Disease
• CONFIRM Trial Final Analysis of Overall Survival: Fulvestrant 500 versus 250 mg
• Neoadjuvant Chemotherapy in Women 35 and Under
• Sentinel Lymph Node Biopsy before or after Neoadjuvant Chemotherapy: Final Results from the SENTINA Trial
• Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial